Regencell Bioscience Holdings Stock Analysis

Regencell Stock Analysis Notes

About 89.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 2.15. Regencell Bioscience recorded a loss per share of 0.33. The entity last dividend was issued on the 1st of December 2017. Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Regencell Bioscience Holdings contact the company at 852 2155 0823 or learn more at https://www.regencellbioscience.com.

Regencell Bioscience Investment Alerts

Regencell Bioscience Upcoming and Recent Events

Regencell Bioscience Environmental, Social, and Governance (ESG) Scores

Regencell Bioscience Thematic Classifications

Regencell Stock Institutional Investors

Note, although Regencell Bioscience's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Regencell Market Capitalization

The company currently falls under 'Micro-Cap' category with a total capitalization of 82.24 M.

Regencell Profitablity

Management Efficiency

Regencell Bioscience has Return on Asset of (0.2811) % which means that on every $100 spent on assets, it lost $0.2811. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4318) %, meaning that it generated no profit with money invested by stockholders. Regencell Bioscience's management efficiency ratios could be used to measure how well Regencell Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At present, Regencell Bioscience's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.04, whereas Return On Equity is projected to grow to (0.13). At present, Regencell Bioscience's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.05, whereas Total Assets are forecasted to decline to about 8 M.

Technical Drivers

As of the 2nd of December, Regencell Bioscience holds the Risk Adjusted Performance of 0.0123, coefficient of variation of 24364.1, and Semi Deviation of 6.48. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regencell Bioscience, as well as the relationship between them.

Regencell Bioscience Price Movement Analysis

Regencell Bioscience Insider Trading Activities

Regencell Bioscience Outstanding Bonds

Regencell Bioscience Predictive Daily Indicators

Regencell Bioscience Corporate Filings

Regencell Bioscience Forecast Models

Regencell Bioscience's time-series forecasting models are one of many Regencell Bioscience's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Regencell Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Regencell Bioscience prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Regencell shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Regencell Bioscience. By using and applying Regencell Stock analysis, traders can create a robust methodology for identifying Regencell entry and exit points for their positions.

When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.